NVAX (Novavax) Days Payable : 244.82 (As of Mar. 2025)

View and export this data going back to 1995. Start your Free Trial

What is Novavax Days Payable?

Novavax's average Accounts Payable for the three months ended in Mar. 2025 was $38 Mil. Novavax's Cost of Goods Sold for the three months ended in Mar. 2025 was $14 Mil. Hence, Novavax's Days Payable for the three months ended in Mar. 2025 was 244.82.

The historical rank and industry rank for Novavax's Days Payable or its related term are showing as below:

NVAX' s Days Payable Range Over the Past 10 Years
Min: 69.46 Med: 156.8 Max: 185.34
Current: 125.46

During the past 13 years, Novavax's highest Days Payable was 185.34. The lowest was 69.46. And the median was 156.80.

NVAX's Days Payable is ranked better than
51.13% of 706 companies
in the Biotechnology industry
Industry Median: 121.27 vs NVAX: 125.46

Novavax's Days Payable increased from Mar. 2024 (146.67) to Mar. 2025 (244.82). It may suggest that Novavax delayed paying its suppliers.

Novavax Days Payable Historical Data

The historical data trend for Novavax's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Days Payable Chart

Novavax Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

69.46

185.34

156.80

Novavax Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Days Payable	Get a 7-Day Free Trial															146.67	135.85	103.47	123.30	244.82

Competitive Comparison of Novavax's Days Payable

For the Biotechnology subindustry, Novavax's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novavax's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novavax's Days Payable distribution charts can be found below:

* The bar in red indicates where Novavax's Days Payable falls into.

Save Embed

;

Save Embed

;

Novavax Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Novavax's Days Payable for the fiscal year that ended in Dec. 2024 is calculated as

	Days Payable (A: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2023 )	+	Accounts Payable (A: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2024 )	*	Days in Period
=	( (132.61	+	41.579)	/	2 )	/	202.739	*	365
=	87.0945					/	202.739	*	365
=	156.80

Novavax's Days Payable for the quarter that ended in Mar. 2025 is calculated as:

	Days Payable (Q: Mar. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2024 )	+	Accounts Payable (Q: Mar. 2025 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2025 )	*	Days in Period
=	( (41.579	+	34.162)	/	2 )	/	14.115	*	365 / 4
=	37.8705					/	14.115	*	365 / 4
=	244.82

Novavax Days Payable Related Terms

Thank you for viewing the detailed overview of Novavax's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria

Address

700 Quince Orchard Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Executives

James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100